Nasus Pharma Ltd
NSRX7.260USD
+0.890+13.97%
收盤 12/19, 16:00（美東）報價延遲15分鐘
65.77M總市值
虧損本益比TTM
關於 Nasus Pharma Ltd 公司
Nasus Pharma Ltd is an Israel-based pharmaceutical company. The Company conducts ins business activities as a pharmaceutical preparation and intranasal powder-based drug delivery systems manufacturer. Its microsphere technology enables rapid, non-invasive administration of medications for conditions such as anaphylaxis and opioid overdose among others. Nasus Pharma Ltd's formulations are designed for relatively fast absorption, ease of use, and effectiveness in critical situations (such as emergency use). The Company's products predominantly aim to improve access to life-saving treatments by allowing easy administration by caregivers or non-professionals, as well as medical doctors and emergency nurses.
Nasus Pharma Ltd簡介
公司代碼NSRX
公司名稱Nasus Pharma Ltd
上市日期Aug 13, 2025
CEOTeleman (Dan)
員工數量- -
證券類型Ordinary Share
年結日Aug 13
公司地址Yigal Alon 65
城市TEL AVIV-YAFO
上市交易所NASDAQ OMX – NASDAQ Basic Amex
國家Israel
郵編- -
電話97237326616
網址https://www.nasuspharma.com
公司代碼NSRX
上市日期Aug 13, 2025
CEOTeleman (Dan)
Nasus Pharma Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.90M
+3.00%
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
+2.32%
Mr. David Silberman, CPA
Mr. David Silberman, CPA
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Oren Elmaliach
Mr. Oren Elmaliach
Director of Finance
Director of Finance
--
--
Dr. Tair Lapidot, Ph.D.
Dr. Tair Lapidot, Ph.D.
Vice President of Research and Development and Clinical Development
Vice President of Research and Development and Clinical Development
--
--
Galia Temtsin Kryaz
Galia Temtsin Kryaz
Director of CMC and Product Development
Director of CMC and Product Development
--
--
Mr. Ronnie Hershman
Mr. Ronnie Hershman
Independent Director
Independent Director
--
--
Isaac Israel
Isaac Israel
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Dan Teleman
Mr. Dan Teleman
Chief Executive Officer
Chief Executive Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.90M
+3.00%
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
+2.32%
Mr. David Silberman, CPA
Mr. David Silberman, CPA
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Oren Elmaliach
Mr. Oren Elmaliach
Director of Finance
Director of Finance
--
--
Dr. Tair Lapidot, Ph.D.
Dr. Tair Lapidot, Ph.D.
Vice President of Research and Development and Clinical Development
Vice President of Research and Development and Clinical Development
--
--
Galia Temtsin Kryaz
Galia Temtsin Kryaz
Director of CMC and Product Development
Director of CMC and Product Development
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Gilboa (Udi)
21.09%
Megiddo (Dalia)
20.96%
Hershman Holdings L.L.C.
9.89%
Capital Point Ltd
6.38%
Phoenix Solutions Ltd
4.76%
其他
36.92%
持股股東
持股股東
佔比
Gilboa (Udi)
21.09%
Megiddo (Dalia)
20.96%
Hershman Holdings L.L.C.
9.89%
Capital Point Ltd
6.38%
Phoenix Solutions Ltd
4.76%
其他
36.92%
股東類型
持股股東
佔比
Individual Investor
43.95%
Corporation
21.03%
Investment Advisor
0.04%
其他
34.98%
機構持股
更新時間: 9月12日 週五
更新時間: 9月12日 週五
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
7
5.35M
59.33%
+5.35M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Gilboa (Udi)
1.85M
20.48%
+1.85M
--
Aug 12, 2025
Megiddo (Dalia)
1.85M
20.48%
+1.85M
--
Aug 12, 2025
Hershman Holdings L.L.C.
477.01K
5.29%
+477.01K
--
Aug 12, 2025
Capital Point Ltd
575.13K
6.38%
+575.13K
--
Aug 14, 2025
Phoenix Solutions Ltd
429.31K
4.76%
+429.31K
--
Aug 12, 2025
Krayz (Galia Temtsin)
171.72K
1.91%
+171.72K
--
Aug 12, 2025
Lapidot (Tair Ph.D.)
10.00
0%
+10.00
--
Aug 12, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Nasus Pharma Ltd的前五大股東是誰？
Nasus Pharma Ltd的前五大股東如下：
Gilboa (Udi)持有股份：1.85M佔總股份比例：20.48%。
Megiddo (Dalia)持有股份：1.85M佔總股份比例：20.48%。
Hershman Holdings L.L.C.持有股份：477.01K佔總股份比例：5.29%。
Capital Point Ltd持有股份：575.13K佔總股份比例：6.38%。
Phoenix Solutions Ltd持有股份：429.31K佔總股份比例：4.76%。
Gilboa (Udi)持有股份：1.85M佔總股份比例：20.48%。
Megiddo (Dalia)持有股份：1.85M佔總股份比例：20.48%。
Hershman Holdings L.L.C.持有股份：477.01K佔總股份比例：5.29%。
Capital Point Ltd持有股份：575.13K佔總股份比例：6.38%。
Phoenix Solutions Ltd持有股份：429.31K佔總股份比例：4.76%。
Nasus Pharma Ltd的前三大股東類型是什麼？
Nasus Pharma Ltd 的前三大股東類型分別是：
Gilboa (Udi)
Megiddo (Dalia)
Hershman Holdings L.L.C.
Gilboa (Udi)
Megiddo (Dalia)
Hershman Holdings L.L.C.
有多少機構持有Nasus Pharma Ltd(NSRX)的股份？
截至2025Q3，共有7家機構持有Nasus Pharma Ltd的股份，合計持有的股份價值約為5.35M，占公司總股份的59.33% 。與--相比，機構持股有所增加，增幅為--。
哪個業務部門對Nasus Pharma Ltd的收入貢獻最大？
在--，--業務部門對Nasus Pharma Ltd的收入貢獻最大，創收--，占總收入的--% 。
